View
28
Download
2
Category
Preview:
Citation preview
YEDA’s BUSINESS CLUB
Welcome to
2016
2
JUNE2015
3 YEARS COLLABORATION FOR DETERMINING CONSUMER UNDERSTANDING OF VARIOUS STIMULATIONS.
UNILEVER – SOBEL
3
JUNE2015
A NEW COMPANY AIMING TO DEVELOP BACTERIOPHAGE-BASED THERAPIES FOR THE TREATMENT AND PREVENTION OF DISEASES STEMMING FROM THE MICROBIOME.
MBCURE
4
JULY2015
RSeT™ is a defined medium that allows researchers to revert human primed pluripotent stem cells to a naive-like state. RSeT™ also enables researchers to culture human naive-like pluripotent stem cells long-term and supports this rapidly expanding field of human pluripotent stem cell (hPSC) research.
STEMCELL
5
NOVEMBER2015
PERSONALIZED NUTRITION AND ACTIONABLE INSIGHTS THAT ALLOW YOU TO LIVE HEALTHIER AND MAINTAIN NORMAL BLOOD SUGAR LEVELS.
DAYTWO
BASED ON THE WORK OF PROF. SEGAL AND PROF. ELINAV
NOVEMBER2015 cont’d
A collaboration agreement allowing easy access to Korean companies to WIS technologies.
6
KORIL-RDF
ImmunArray launches a new blood test for lupus which is being rolled out nationally. This will provide a wider group of rheumatologists with a simple, accurate means for ruling out whether a patient is suffering from the chronic, autoimmune disease that affects 1.5 million Americans, mostly women between the ages of 18 and 60.
ImmunArray
7
NOVEMBER2015 cont’d
AB2 Bio Ltd. achieved a medical breakthrough in the treatment of systemic inflammation. Drug candidate effective in treating a baby girl carrying a newly identified, potentially fatal, genetic mutation causing severe systemic inflammation.
AB2 BIO
I L 1 8 B D WA S D I S C O V E R E D B Y D R . D A N I E L A N O V I K
8
DECEMBER2015
WEIZMANN INSTITUTE DRUG, TOOKAD® SOLUBLE, APPROVED FOR PROSTATE CANCER THERAPY IN MEXICO and ISRAEL
TOOKAD® SOLUBLE
A therapy invented at the Weizmann Institute of Science and clinically developed in collaboration with Steba Biotech (France) has been approved for the treatment of early-stage prostate cancer by Mexico’s Secretariat of Health. The approval comes in the wake of the recent successful completion of a Phase III clinical trial on more than 400 patients at 55 medical centers in 11 European countries, as well as a confirmatory, Phase III study on 80 patients in Mexico.
9
DECEMBER2015 cont’
KADIMASTEM REACHED AGREEMENTS WITH THE FDA REGARDING THE FRAMEWORK OF THE CLINICAL TRIALS IN HUMANS FOR THE TREATMENT OF ALS.
KADIMASTEM
10
DECEMBER2015 cont’d
Sun Pharmaceutical Industries Ltd. entered into a tripartite research and option agreement with Weizmann Institute of Science and Spain's Health Research Institute of Santiago de Compostela (IDIS) to develop breakthrough products for the treatment of neurological diseases like brain stroke; as well as glioblastoma.
SUNPHARMA
11
FEBRUARY2016
AWARDED FOR ITS "INNOVATION POTENTIAL" AT THE INTERNATIONAL QUALITY INNOVATION OF THE YEAR CEREMONY IN ESTONIA.
NEWCO2FUELS (NCF)
FEBRUARY2016
MERCK AND WEIZMANN INSTITUTE SIGN NEW FRAMEWORK AGREEMENT ON RESEARCH COLLABORATION
12
MERCK-WEIZMANN
AS PART OF THE NEW FRAMEWORK AGREEMENT MERCK WILL FUND EACH OF THE TWO RESEARCH AREAS WITH UP TO € 1 MILLION PER YEAR OVER A 3-YEAR PERIOD.
13
MARCH2016
A NEW SPINOUT COMPANY RONDIX WAS BORN.
RONDINX
BASED ON THE WORK OF PROF. SEGAL AND PROF. ELINAV
NEXT GENERATION SEQUENCING AND ANALYZING OF THE MICROBIOME.
14
MARCH2016
FROM A SINGLE PATENTTO THREE DRUGS
$1,081 MILLIONErbitux® Merck and Eli Lillymetastatic colorectal cancer
$500 M (EST 2016)Portrazza® Eli LillyLung cancer
$359 MILLIONVectibix® AMGENColorectal cancer
Prof. Sela and colleagues discovered that EGFR-inhibiting antibodies produce a synergistic anticancer effect when used together with chemotherapy
The three EGFR blockers are saving the lives of hundreds of thousands of cancer patients all over the world
EGFR BLOCKERS
15
MARCH2016
NOVEL ANTIBODIES BASED THERAPIES TARGETING MMP 9.
MABTRIX
BASED ON THE WORK OF PROF. IRIT SAGI
Core technology is based on a molecular structure and biophysics platform which enables to identify and design highly potent and extremely selective monoclonal antibody against a physiological conformation of target molecule
16
THANK YOU !
17
Recommended